# Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

> **NCT05226923** · PHASE1 · COMPLETED · sponsor: **Sumitovant Biopharma, Inc.** · enrollment: 123 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** KSP-1007
- **OTHER:** Placebo:0.9% sodium chloride
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT05226923
- **Lead sponsor:** Sumitovant Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-12
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226923, "Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05226923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*